Polyphenolic Fraction Obtained From Thalassia testudinum Marine Plant and Thalassiolin B Exert Cytotoxic Effects in Colorectal Cancer Cells and Arrest Tumor Progression in a Xenograft Mouse Model

Marine plants are important sources of pharmacologically active metabolites. The aim of the present work was to evaluate the cytotoxic and antitumor activity of a polyphenolic fraction obtained from Thalassia testudinum marine plant and thalassiolin B in human colorectal cancer cells. Human cancer cell lines, including HCT15, HCT116, SW260, and HT29 were treated with tested products for cytotoxicity evaluation by crystal violet assay. The potential proapoptotic effect of these natural products was assessed by flow cytometry in HCT15 cells at 48 h using Annexin V-FITC/propidium iodide. In addition, reactive oxygen species (ROS) generation was measured by fluorescence using DCFH-DA staining, and sulfhydryl concentration by spectrophotometry. The in vivo antitumor activity of the polyphenolic fraction (25 mg/kg) was evaluated in a xenograft model in nu/nu mice. In vivo proapoptotic effect was also evaluated by immunohistochemistry using anti-caspase 3 and anti-Bcl-2 antibodies. The results showed that tested products exert colorectal cancer cell cytotoxicity. Besides, the tested products induced a significant increase (p < 0.05) of intracellular ROS generation, and a depletion of sulfhydryl concentration in HCT15 cells. The polyphenolic fraction arrested tumor growth and induced apoptosis in the xenograft mice model. These results demonstrate the cytotoxic activity of T. testudinum metabolites associated, at least, with ROS overproduction and pro-apoptotic effects. Here we demonstrated for the first time the antitumor activity of a T. testudinum polar extract in a xenograft mice model. These results suggest the potential use of T. testudinum marine plant metabolites as adjuvant treatment in cancer therapy.

Download Full-text

Importance of the fatty acid chain length on in vitro and in vivo anticancer activity of fattigation-platform albumin nanoparticles in human colorectal cancer xenograft mice model

Journal of Controlled Release ◽

10.1016/j.jconrel.2020.05.001 ◽

2020 ◽

Vol 324 ◽

pp. 55-68

Author(s):

Chulhun Park ◽

Namhyun Baek ◽

Raimar Loebenberg ◽

Beom-Jin Lee

Keyword(s):

Colorectal Cancer ◽

Fatty Acid ◽

Mice Model ◽

Human Colorectal Cancer ◽

Albumin Nanoparticles ◽

Fatty Acid Chain ◽

Xenograft Mice Model ◽

Xenograft Mice

Download Full-text

Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas

Cancers ◽

10.3390/cancers13184648 ◽

2021 ◽

Vol 13 (18) ◽

pp. 4648

Author(s):

Eva Lhuissier ◽

Juliette Aury-Landas ◽

Marion Lenté ◽

Karim Boumediene ◽

Catherine Baugé

Keyword(s):

Tumor Volume ◽

Mice Model ◽

Antitumoral Effect ◽

Viable Cells ◽

Epigenetic Drug ◽

Xenograft Mice Model ◽

Xenograft Mice ◽

Tumoral Cells

Background: We have previously shown that 3-Deazaneplanocin A (DZNep) induces apoptosis in chondrosarcomas. Herein, we tested whether the combination of this epigenetic drug to a standard anticancer therapy may enhance the response to each drug in these bone tumors. Methods: Two chondrosarcoma cell lines (SW1353 and JJ012) were cultured in the presence of DZNep and/or cisplatin. Cell growth was evaluated by counting viable cells, and apoptosis was determined by Apo2.7 expression by flow cytometry. In vivo, the antitumoral effect of the DZNep/cisplatin combination was assessed through measurements of tumor volume of JJ012 xenografts in nude mice. Results: In vitro, the DZNep/cisplatin combination reduced cell survival and increased apoptosis compared to each drug alone in chondrosarcomas, but not in normal cells (chondrocytes). This enhancement of the antitumoral effect of the DZNep/cisplatin combination required a priming incubation with DZNep before the co-treatment with DZNep/cisplatin. Furthermore, in the chondrosarcoma xenograft mice model, the combination of both drugs more strongly reduced tumor growth and induced more apoptosis in tumoral cells than each of the drugs alone. Conclusion: Our results show that DZNep exposure can presensitize chondrosarcoma cells to a standard anticancer drug, emphasizing the promising clinical utilities of epigenetic-chemotherapeutic drug combinations in the future treatment of chondrosarcomas.

Download Full-text

Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer

Cancer Cell International ◽

10.1186/s12935-020-01668-z ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Xianjun Sun ◽

Wenhou Hou ◽

Xin Liu ◽

Jie Chai ◽

Hongliang Guo ◽

...

Keyword(s):

Colorectal Cancer ◽

Cell Viability ◽

Research Effort ◽

Translesion Synthesis ◽

Xenograft Model ◽

Mice Model ◽

Cell Viability Assay ◽

Viability Assay ◽

Xenograft Mice Model

Abstract Background Despite an enormous research effort, patients diagnosed with advanced colorectal cancer (CRC) still have low prognosis after surgical resection and chemotherapy. The major obstacle for CRC treatment is chemoresistance to front line anti-cancer drugs, such as 5-fluorouracil (5-FU) and oxaliplatin. However, the mechanism of chemoresistance to these drugs remains unclear. Methods Cell viability to 5-FU and oxaliplatin was measured by the CellTiter-Glo® 2.0 Cell Viability Assay. The endogenous REV7 protein in CRC cells was detected by western blotting. The translesion synthesis (TLS) events were measured by plasmid-based TLS efficiency assay. Cell apoptosis was evaluated by caspase3/7 activity assay. The in vivo tumor progression was analyzed by HT29 xenograft mice model. Results In this study, we found that expression of REV7, which is a key component of translesion synthesis (TLS) polymerase ζ (POL ζ), is significantly increased in both 5-FU and oxaliplatin resistant CRC cells. TLS efficiency analysis revealed that upregulated REV7 protein level results in enhanced TLS in response to 5-FU and oxaliplatin. Importantly, inhibition of REV7 by CRISPR/Cas9 knockout exhibited significant synergy with 5-FU and oxaliplatin in cell culture and murine xenograft model. Conclusion These results suggest that combination of REV7 deficiency and 5-FU or oxaliplatin has strong inhibitory effects on CRC cells and identified REV7 as a promising target for chemoresistant CRC treatment.

Download Full-text

Stichoposide C Induces Apoptosis through the Generation of Ceramide in Leukemia and Colorectal Cancer Cells and Shows In Vivo Antitumor Activity

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-0655 ◽

2012 ◽

Vol 18 (21) ◽

pp. 5934-5948 ◽

Cited By ~ 35

Author(s):

Seong-Hoon Yun ◽

Eun-Seon Park ◽

Sung-Won Shin ◽

Yong-Woo Na ◽

Jin-Yeong Han ◽

...

Keyword(s):

Colorectal Cancer ◽

Antitumor Activity ◽

Cancer Cells ◽

In Vivo Antitumor Activity ◽

Colorectal Cancer Cells

Download Full-text

Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo

Oncotarget ◽

10.18632/oncotarget.5475 ◽

2015 ◽

Vol 6 (34) ◽

pp. 35991-36002 ◽

Cited By ~ 4

Author(s):

Chun-Han Chen ◽

Chia-Hwa Lee ◽

Jing-Ping Liou ◽

Che-Ming Teng ◽

Shiow-Lin Pan

Keyword(s):

Colorectal Cancer ◽

Antitumor Activity ◽

Cancer Cells ◽

Molecular Mechanisms ◽

Human Colorectal Cancer ◽

Colorectal Cancer Cells ◽

Human Colorectal Cancer Cells

Download Full-text

The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study

Cells ◽

10.3390/cells8101268 ◽

2019 ◽

Vol 8 (10) ◽

pp. 1268 ◽

Cited By ~ 5

Author(s):

Kuan-Lin Kuo ◽

Shing-Hwa Liu ◽

Wei-Chou Lin ◽

Po-Ming Chow ◽

Yu-Wei Chang ◽

...

Keyword(s):

Antitumor Effect ◽

Enzyme Inhibitor ◽

Critical Role ◽

Deubiquitinating Enzymes ◽

Mice Model ◽

Bladder Urothelial Carcinoma ◽

Xenograft Mice Model ◽

Xenograft Mice

After chemotherapy for the treatment of metastatic bladder urothelial carcinoma (UC), most patients inevitably encounter drug resistance and resultant treatment failure. Deubiquitinating enzymes (DUBs) remove ubiquitin from target proteins and play a critical role in maintaining protein homeostasis. This study investigated the antitumor effect of PR-619, a DUBs inhibitor, in combination with cisplatin, for bladder UC treatment. Our results showed that PR-619 effectively induced dose- and time-dependent cytotoxicity, apoptosis, and ER-stress related apoptosis in human UC (T24 and BFTC-905) cells. Additionally, co-treatment of PR-619 with cisplatin potentiated cisplatin-induced cytotoxicity in UC cells and was accompanied by the concurrent suppression of Bcl-2. We also proved that Bcl-2 overexpression is related to the chemo-resistant status in patients with metastatic UC by immunohistochemistry (IHC) staining. In a xenograft mice model, we confirmed that PR-619 enhanced the antitumor effect of cisplatin on cisplatin-naïve and cisplatin-resistant UCs. Our results demonstrated that PR-619 effectively enhanced the cisplatin-induced antitumor effect via concurrent suppression of the Bcl-2 level. These findings provide promising insight for developing a therapeutic strategy for UC treatment.

Download Full-text

Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer

Scientific Reports ◽

10.1038/s41598-021-96578-z ◽

2021 ◽

Vol 11 (1) ◽

Cited By ~ 1

Author(s):

Belén L. Bouzo ◽

Saínza Lores ◽

Raneem Jatal ◽

Sandra Alijas ◽

María José Alonso ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Cells ◽

Cancer Drug ◽

Mice Model ◽

Combination Strategy ◽

Natural Ligand ◽

Colorectal Cancer Cells

AbstractColorectal cancer is the third most frequently diagnosed cancer malignancy and the second leading cause of cancer-related deaths worldwide. Therefore, it is of utmost importance to provide new therapeutic options that can improve survival. Sphingomyelin nanosystems (SNs) are a promising type of nanocarriers with potential for association of different types of drugs and, thus, for the development of combination treatments. In this work we propose the chemical modification of uroguanylin, a natural ligand for the Guanylyl Cyclase (GCC) receptor, expressed in metastatic colorectal cancer tumors, to favour its anchoring to SNs (UroGm-SNs). The anti-cancer drug etoposide (Etp) was additionally encapsulated for the development of a combination strategy (UroGm-Etp-SNs). Results from in vitro studies showed that UroGm-Etp-SNs can interact with colorectal cancer cells that express the GCC receptor and mediate an antiproliferative response, which is more remarkable for the drugs in combination. The potential of UroGm-Etp-SNs to treat metastatic colorectal cancer cells was complemented with an in vivo experiment in a xenograft mice model.

Download Full-text

Synthetic investigation on chirally pure Mannich derivatives of pseudophenylpropanolamine and their anticancer properties against HepG-2 cells with inhibition of JAK2/STAT3

RSC Advances ◽

10.1039/c6ra22480f ◽

2016 ◽

Vol 6 (99) ◽

pp. 96946-96962 ◽

Cited By ~ 6

Author(s):

C. Balachandran ◽

K. Chennakesava Rao ◽

Y. Arun ◽

N. Emi ◽

N. Yamamoto ◽

...

Keyword(s):

Mice Model ◽

Anticancer Properties ◽

Stat3 Signaling ◽

Stat3 Signaling Pathway ◽

Xenograft Mice Model ◽

Xenograft Mice ◽

Derivatives Of ◽

Synthetic Investigation

In vitro and in vivo anticancer activity of compound 3a was proved as a novel blocker of JAK2/STAT3 signaling pathway and exerts both anti-proliferative and apoptotic activities in HepG-2 cells with xenograft mice model.

Download Full-text